Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Cancer Immunol Res. 2019 Nov 12;8(1):94–107. doi: 10.1158/2326-6066.CIR-19-0373

Figure 1. SBRT synergistically enhanced the antitumor efficacy of modified FOLFIRINOX in a murine orthotopic model of pancreatic cancer.

Figure 1.

(A) Schematic of the experimental design. (B-D) Tumor growth was analyzed by IVIS twice a week. (B) Representative IVIS images from day 19 after tumor implantation. (C) Tumor growth curve based on IVIS imaging. Data represent at least 2 independent experiments (n=5–7 mice/group). *p<0.05, mFX + SBRT compared with mFX treatment group by one-way ANOVA with Dunnett post-test. (D) Kaplan Meier survival plots for tumor-bearing mice in the various treatment groups. Shown is the percentage of tumor-free mice. **p<0.01, mFX + SBRT compared with mFX treatment group, by log-rank (Mantel-Cox) test. (E, F) C57BL/6J mice were injected with Panc 02-luc in tail of pancreas, and treated with mFX and/or SBRT as in (A). Tumor growth was monitored by IVIS and survival was observed. (E) Tumor growth curve based on IVIS imaging. Data shown are mean ± SEM (n=5 mice/group). *p<0.05, mFX + SBRT compared with mFX treatment group by one-way ANOVA with Dunnett post-test. (F) Kaplan Meier survival curve. *p<0.05, mFX + SBRT compared with mFX treatment group by log-rank (Mantel-Cox) test.